By Teresa Conrick
The newest research on AUTISM shows that we are getting closer and closer to the true factors that affect so many children. It's time to say so long to genetics and psychiatry as THE answers to what has been happening to a generation of children. This quote from the CDC -- More people than ever before are being diagnosed with ASD -- is only partially true. Yes, "more" and more but not people, as that is misleading, but CHILDREN, and that is ----- devastating. My daughter, Megan, is one of them. Her diagnosis of Autism came about after vaccinations. Seizures and an autoimmune diagnosis were to follow. Immune dysfunction, OCD and tics continue to haunt her and SO many other children who have AUTISM, PANDAS and PANS. A future name to capture the significant immune horrors and behaviors of these children and young adults should be -- AUTOIMMUNE ENCEPHALITIS . Research is looking at how this could be happening: One way the microbiome could contribute to this process is via molecular mimicry of PANDAS (Pediatric Autoimmune Neuropsychiatric Disorder Associated with Streptococcal infections), which sometimes co-occurs with autism. It was proposed that the presence of certain bacteria can lead to the formation of antibodies reactive with the basal ganglia of the brain resulting in behavioral abnormalities.112
There are doctors treating the immune issues of Autism and noting up to 50% of their cases are children with this co-occurrence of PANDAS and PANS. Over the years, I have written about this topic, Many parents report their child exhibiting the first signs of PANDAS and PANS after vaccines , so as a refresher, here are updated definitions:
Pediatric Acute-onset Neuropsychiatric Syndrome (PANS) is a clinical diagnosis given to children who have a dramatic – sometimes overnight – onset of neuropsychiatric symptoms including obsessions/compulsions or food restriction. They are often diagnosed with obsessive-compulsive disorder (OCD) or an eating disorder, but the sudden onset of symptoms separates PANS from these other disorders. In addition, they may have symptoms of depression, irritability, anxiety, and have difficulty with schoolwork. The cause of PANS is unknown in most cases but is thought to be triggered by infections, metabolic disturbances, and other inflammatory reactions.
Like PANS, children with Pediatric Autoimmune Neuropsychiatric Disorder Associated with Streptococcal Infections (PANDAS) have an acute onset – within 2 to 3 days – of neuropsychiatric symptoms, specifically OCD or tics (involuntary, purposeless movements). However, PANDAS patients test positive for a recent streptococcal infection, such as strep throat, peri-anal strep or scarlet fever. Like PANS patients, they also may suffer from uncontrollable emotions, irritability, anxiety and loss of academic ability and handwriting skills. Although PANDAS was identified as a medical syndrome more than a decade before PANS, it has been classified as a subset of PANS. To date, PANDAS is the only known subset of PANS, but we may discover more causes in the future.
In some recent reading on the immune system, I came upon this information regarding antibiotic resistance from CDC that just seemed incorrect and troubling, especially as we see increases in too many children with immune dysfunction. We must be vigilant when we see reports or research that are just NOT honest.:
Vaccination: There are few vaccines for antibiotic-resistant bacteria, but the S. pneumoniae vaccine has proven that an effective vaccine can reduce antibiotic resistance rates. The vaccine targets certain types of the bacteria, even if it is a resistant type, and reduces the overall number of infections, including those that are caused by resistant strains. The first version of the vaccine was introduced in 2000 and reduced the frequency of antibiotic-resistant infections, but it did not protect against a particular strain of S. pneumoniae called serotype 19A. This strain became increasingly resistant to antibiotics and caused more infections because the vaccine did not offer protection. A new version of the vaccine, approved for use in 2010, protects against serotype 19A. As a result, the rate of resistant pneumococcal infections is decreasing.
There is so much wrong with that statement. I boldfaced the phrases and sentences that seem to contradict MUCH research and will present research below to address these false points. This is not the first time that I have written about immune system damage via the vaccination program. Let's take a look at what CDC is NOT reporting.
PCV7 CAUSED INCREASED INFECTIONS AND NEW TYPES OF STREP PNEUMONIA SEROTYPES
Emergence of Streptococcus pneumoniae Serotypes 19A, 6C, and 22F and Serogroup 15 in Cleveland, Ohio, in Relation to Introduction of the Protein-Conjugated Pneumococcal Vaccine:
● A 7-valent conjugate pneumococcal vaccine (PCV7) was introduced in 2000 ● This vaccine, which was introduced in the United States in 2000, contains polysaccharide from the 7 serotypes that are commonly responsible for invasive disease in children (4, 6B, 9V, 14, 18C, 19F, and 23F), ● The expectation of cross-coverage by PCV7 of vaccine-related serotypes was not fulfilled, and serotype 19A, above all, has filled the gap left by the effectiveness of the vaccine ● there were statistically significant increases in the incidence of vaccine-related serotypes for adult (206.7%) and pediatric (900%) noninvasive isolates. (Pneumococcal infections are defined as invasive or non-invasive according to the body site they affect. Invasive pneumococcal disease (IPD) is caused by infection of normally invasive sites e.g. blood and cerebrospinal fluid (CSF)...Non-invasive forms of the infection commonly cause middle ear infection (otitis media), exacerbations of bronchitis, and pneumonia.) ● The incidence of infection due to 6 serotypes (6C, 15A, 15B, 15C, 19A, and 22F) increased after the introduction of PCV7.
● A particularly notable finding in our study is the 900% increase in noninvasive pediatric vaccine-related isolates that was associated with serotypes 19A...serotype 19A frequently recovered from middle ear fluid specimens. ● It is noteworthy that serotype 19A—the original multidrug-resistant serotype reported from South Africa in 1978 —emerged in the United States after the introduction of PCV7 in 2000, and many of these isolates are multidrug resistant.
Points to repeat -- After the pneumococcal vaccine (PCV7) was introduced in 2000, data shows that NEW, non-vaccine types of serotypes INCREASED, as well as vaccine-type INCREASES of infection. The 19A serotype caused INCREASED (900%!) ear infections as well as cases of pneumonia. The use of the vaccine shows "statistically significant" increases in direct infection as well as the "herd" effect of INCREASED infections. The COMMUNITY IMMUNITY was shown to be negatively affected by the PCV7 vaccine as it caused increased incidences of pneumonia infection, skyrocketing ear infections, and dangerous antibiotic resistance. More effects were to come with each new type of pneumococcal vaccine.
MORE STUDIES SHOW INDIVIDUAL IMMUNITY AND "COMMUNITY IMMUNITY" IN JEOPARDY
- Involved in maintenance and dissemination of pathogens across the population
- May also govern the acquisition of antibiotic resistance genes among bacteria
- Several S. pneumoniae vaccines in clinical use:
- Pneumococcal polysaccharide-based (PPS)
- Pneumovax – 23 polysaccharide
- Pneumococcal conjugate vaccines
- PCV7, PCV10, PCV13 (Prevnar)
- PCV programs have been successful in decreasing incidence of pneumococcal diseases… but eliminating the strain-specific serotypes in vaccine is followed by emergence of non-vaccine serotypes in the population.
- We need a better mechanistic understanding of inter-microbial interactions
- How elimination or reduction of individual microbial populations alters presence, abundance, diversity, and behavior of others
- Long-term view of vaccinations – alter carriage patterns in populations over time
- Short-term benefits versus long-term implications
In 2001-2002, of the serotypes found in PCV-7, types 14, 19F, 23F, and 6B were the most prevalent erythromycin-resistant serotypes. In 2007-2008, types19A, 15A, and 6C emerged as the most common serotypes among erythromycin-resistant isolates. The increase in macrolide resistance over the surveillance period represented both an expansion of serotypes, with high macrolide resistance at the start of the period (e.g., 15A), and acquisition of macrolide resistance within specific serotypes (e.g., 19A), either through capsular switching or introduction of novel clones into the region.
WOW so much evidence! And here is CDC again trying to downplay this very scientific effect:
Treatment of pneumococcal infections with penicillin and other drugs is not as effective as it used to be, because some strains of the disease have become resistant to these drugs. This makes prevention of the disease, through vaccination, even more important.
Well, the VACCINE is CAUSING THESE PROBLEMS It appears CDC is boldly pushing the vaccine although more and more research sounds the alarm that THE VACCINE is causing antibiotic resistance, ear infections and pneumonia. It is not hard to see how this science can play out in a child developing immune dysfunction -- PANDAS and PANS.
The introduction of pneumococcal conjugate vaccines has led to the emergence of non-vaccine serotypes, which contributed to invasive pneumococcal disease in Canada and worldwide....A significant increase in the prevalence of non-13-valent pneumococcal conjugate vaccine (PCV-13)-included serotypes 22F, 15A, and 8 was observed from 2009 to 2013 in Ontario (all p values<0.01). In this study, whole genome sequencing was conducted on the 25 isolates of serotype 22F, seven of 15A and 10 of 8 to investigate the population structure and antibiotic resistance. All seven serotype 15A isolates were found to be multidrug resistant.
...in countries where PCV7  or PCV13  was introduced, overall coverage of serotypes by the vaccine gradually decreased because of pneumococcal serotype replacement from vaccine type to nonvaccine type.....PCV13 now has been introduced in >120 countries, and various pneumococcal diseases have decreased as a result. Unfortunately, serotype replacement by non-PCV13 serotypes such as 6C, 15B, 22F, 23A, and 35B has also ensued (13,14,16–18,31).
Expansion of non-PCV13 serotypes was largest following PCV13 introduction. Serotype diversity increased and nonvaccine clones emerged...Pneumococcal vaccination leads to expansion of new or minor serotypes/clones, also in nonvaccinated populations....Importantly, the incidence of non-PCV13 strains was doubled following PCV13 introduction...expanding non-PCV13 strains are more prone to cause disease in individuals with risk factors as compared with many vaccine type strains...The increased serotype diversity in IPD post-PCV is most likely a reflection of the increased number of serotypes prevailing in vaccinated carriers, which will influence the success of current vaccine strategies and must be taken into account when future strategies are developed.
Postvaccination Increase in Serotype 19A Pneumococcal Disease in Norway Is Driven by Expansion of Penicillin-Susceptible Strains of the ST199 Complex
Serotype replacement in invasive pneumococcal disease has been observed after widespread use of the 7-valent pneumococcal conjugate vaccine (PCV7). Replacement is dominated by penicillin-nonsusceptible serotype 19A in several countries. Antibiotic selection pressure has been proposed to interact with immunization, leading to rapid replacement.
pneumococcal disease and PCV13 vaccine type pneumococcal CAP continue to have a significant burden in adults, even after the introduction of PCV13 in children.
........After PCV7 was introduced, serotype 19A pneumococcal strains with penicillin resistance increased (8–10); the change in 2012 to PCV13 covers serotype 19A (11)...... However, in countries where PCV7 or PCV13 was introduced, overall coverage of serotypes by the vaccine gradually decreased because of pneumococcal serotype replacement from vaccine type to nonvaccine type. In particular, increases of nonvaccine serotypes, such as 6C, 15A, 23A, and 35B, have been reported in the United States (13,14) and other countries (15–18)
By targeting a small subset of serotypes, we have begun a vast ecological experiment. In short, we have created a vacant niche, which may be filled by pneumococcal serotypes not included........
It is an experiment and one in which the fallout continues to affect our children both as vaccine recipients and as the research shows, as a nonvaccinated person exposed to someone vaccinated.
The elimination of vaccine type strains in healthy carriage will create profound changes in the entire pneumococcal population structure within a community since different pneumococcal strains most likely coevolve as a result of reciprocal adaptation and counter-adaptation between interacting strains...The increased serotype diversity in IPD post-PCV is most likely a reflection of the increased number of serotypes prevailing in vaccinated carriers, which will influence the success of current vaccine strategies and must be taken into account when future strategies are developed.
This -- believe it or not -- is from a study on CDC's own website, a summary based on extensive research sums it up best -- Vaccination with PCV-7 resulted in a shift in bacterial community composition and structure, with an increase in presence or abundance of several anaerobes, such as Veillonella, Prevotella, Fusobacterium, and Leptotrichia species; gram-positive bacteria, such as Actinomyces and Rothia species, and nonpneumococcal streptococci; and gram-negative Neisseria species…. Together with S. pneumoniae nonvaccine serotype replacement, these effects may further jeopardize the net health benefit of vaccinations with PCV.”
Teresa Conrick is Contributing Editor to Age of Autism.